GlassScriptPhysician profile
Indu Srinivasan
NPI 1972815967
$3,355.68
in general payments reported to CMS, 2019-2025
25 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $110 · 2021: $315 · 2022: $606 · 2023: $328 · 2024: $794 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.01 | 2019-2025 | Linzess, Creon, Viberzi |
| Gilead Sciences, INC. | $447.27 | 2021-2025 | |
| Boston Scientific Corporation | $375.66 | 2022-2025 | Overstitch Endoscopic Suturing System, General - Biliary Devices |
| Janssen Biotech, INC. | $357.33 | 2020-2024 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $312.67 | 2019-2025 | Entyvio, Gattex |
| Intercept Pharmaceuticals, INC. | $159.80 | 2020-2025 | Ocaliva |
| Janssen Scientific Affairs, LLC | $143.49 | 2025 | Tremfya |
| Genzyme Corporation | $99.22 | 2024 | |
| Lilly USA, LLC | $98.50 | 2024-2025 | Omvoh |
| Medtronic, INC. | $90.54 | 2024 | Manoscan |
| Pfizer INC. | $83.97 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $82.40 | 2024-2025 | Iqirvo |
| Shionogi INC | $80.71 | 2019 | |
| Ardelyx, INC. | $76.20 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.35 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $60.21 | 2019 | |
| Qol Medical, LLC | $49.75 | 2019 | |
| Napo Pharmaceuticals INC | $38.12 | 2025 | Mytesi |
| Celgene Corporation | $36.10 | 2023-2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $28.81 | 2023 | Terlivaz |
| Ferring Pharmaceuticals INC. | $20.10 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.34 | 2021 | |
| Shire North American Group INC | $13.81 | 2019 | |
| Aries Pharmaceuticals, INC. | $11.32 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indu Srinivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.